Developing new drugs to target tau proteins for treating Alzheimer's disease
Targeting biologically relevant tau monomers and oligomers using a novel DEL drug discovery platform to treat Alzheimer’s disease and tauopathies
This study is looking for new small molecules that can help reduce the harmful effects of tau proteins, which are linked to Alzheimer's disease, to find better treatments for people dealing with this condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jillion Therapeutics INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11005644 on NIH RePORTER |
What this research studies
This research focuses on identifying small molecules that can bind to tau proteins, which are implicated in Alzheimer's disease and other tauopathies. Using a novel DNA-encoded library (DEL) drug discovery platform, the project aims to modify the biology of tau proteins to block or reduce their toxicity. The approach addresses the challenges of current tau drug discovery methods, which often require large amounts of non-physiological tau protein and complex systems that are not compatible with high-throughput screening. By targeting tau monomers and oligomers, the research seeks to find effective treatments for neurodegenerative diseases characterized by tau pathology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or other tauopathies.
Not a fit: Patients with non-tau related forms of dementia or neurodegenerative diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients suffering from Alzheimer's disease and related conditions.
How similar studies have performed: While targeting tau proteins is a relatively novel approach, there have been promising developments in similar research areas that suggest potential for success.
Where this research is happening
New York, United States
- Jillion Therapeutics INC. — New York, United States (Active)
Researchers
- Principal investigator: Flajolet, Marc — Jillion Therapeutics INC.
- Study coordinator: Flajolet, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.